MCID: OCL022
MIFTS: 50

Ocular Melanoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Eye diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 12 50 52 14
Intraocular Melanoma 12 50 29
Uveal Melanoma 50 69
Malignant Melanoma of Eye 69
Melanoma of the Uvea 50
Melanoma of Eye 12
Eye Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1752

Summaries for Ocular Melanoma

NIH Rare Diseases : 50 intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  the uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  each manifests with different clinical features and symptoms. treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors.  last updated: 11/29/2010

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to retinal detachment and bap1 tumor predisposition syndrome. An important gene associated with Ocular Melanoma is MC1R (Melanocortin 1 Receptor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Ranibizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and lymph node, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 An ocular cancer that has material basis in melanocytes and is located in the eye.

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
id Related Disease Score Top Affiliating Genes
1 retinal detachment 30.0 BRCA2 CDKN2A
2 bap1 tumor predisposition syndrome 11.0
3 ciliary body spindle cell melanoma 10.9
4 iris spindle cell melanoma 10.9
5 choroid spindle cell melanoma 10.9
6 melanoma 10.8
7 baraitser-winter cerebrofrontofacial syndrome 10.7 BAP1 BRCA2
8 bacteremia 10.6 BAP1 BRCA2
9 eccrine sweat gland neoplasm 10.6 BAP1 BRCA2
10 nodular malignant melanoma 10.5 BRCA2 CDKN2A
11 louse-borne relapsing fever 10.5 CDKN2A IL2
12 facial nerve disease 10.5 BAP1 NRAS
13 nasal cavity squamous cell carcinoma 10.5 BRCA2 KIT
14 pediatric cns embryonal cell carcinoma 10.5 BRCA2 CDKN2A
15 superficial basal cell carcinoma 10.5 CDKN2A KIT
16 barbiturate dependence 10.4 CDKN2A IL2
17 pancreatic agenesis 10.4 CDKN2A KIT
18 sublingual gland adenoid cystic carcinoma 10.4 KIT NRAS
19 fallopian tube serous papilloma 10.4 KIT NRAS
20 exertional headache 10.4 CDKN2A KIT
21 brain stem infarction 10.4 KIT NRAS
22 plasmodium ovale malaria 10.4 CDKN2A KIT
23 melanocytic nevus syndrome, congenital, somatic 10.3 MC1R NRAS
24 proliferative glomerulonephritis 10.3 KIT NRAS
25 fibrous meningioma 10.3 CDKN2A NRAS
26 ductal carcinoma in situ 10.3 BRCA2 CDKN2A
27 vaginal yolk sac tumor 10.3 KIT NRAS
28 dyserythropoietic anemia and thrombocytopenia 10.3 KIT NRAS
29 gastrointestinal neuroendocrine tumor 10.3 CDKN2A KIT
30 olfactory neural tumor 10.3 CDKN2A NRAS
31 hydrarthrosis 10.3 KIT NRAS
32 olfactory nerve disease 10.3 IL2 KIT
33 phobic disorder 10.3 CDKN2A NRAS
34 extraosseous osteosarcoma 10.2 CDKN2A KIT
35 epidural neoplasm 10.2 CDKN2A VEGFA
36 distal monosomy 7q36 10.2 BRCA2 VEGFA
37 factitious disorder 10.2 KIT VEGFA
38 post-surgical hypoinsulinemia 10.2 BRCA2 CDKN2A IL2
39 hepatitis 10.2
40 choroiditis 10.2
41 fallopian tube carcinosarcoma 10.1 BRCA2 VEGFA
42 tumor of exocrine pancreas 10.1 CDKN2A VEGFA
43 parotid gland adenoid cystic carcinoma 10.1 IL2 KIT NRAS
44 embryonal rhabdomyosarcoma 10.1 CDKN2A IL2
45 tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria 10.0 KIT VEGFA
46 kidney hypertrophy 10.0 CDKN2A KIT
47 diffuse meningeal melanocytosis 10.0 CDKN2A KIT NRAS
48 vulval paget's disease 10.0 CDKN2A KIT NRAS
49 bone marrow cancer 10.0 CDKN2A KIT NRAS
50 hemolytic anemia 10.0 IL2 KIT VEGFA

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
2 hematopoietic system MP:0005397 10.16 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
3 endocrine/exocrine gland MP:0005379 10.14 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
4 growth/size/body region MP:0005378 10.13 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
5 immune system MP:0005387 10.13 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
6 behavior/neurological MP:0005386 10.12 BRCA2 CDKN2A IL2 KIT MC1R NRAS
7 digestive/alimentary MP:0005381 10.1 BAP1 BRCA2 CDKN2A IL2 KIT NRAS
8 homeostasis/metabolism MP:0005376 10.1 BAP1 BRCA2 CDKN2A CIITA IL2 KIT
9 embryo MP:0005380 10.02 BRCA2 CDKN2A KIT NRAS VEGFA BAP1
10 integument MP:0010771 10 BAP1 BRCA2 CDKN2A KIT MC1R NRAS
11 neoplasm MP:0002006 9.97 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
12 no phenotypic analysis MP:0003012 9.87 IL2 KIT MC1R NRAS VEGFA BAP1
13 limbs/digits/tail MP:0005371 9.83 BRCA2 KIT MC1R NRAS VEGFA
14 liver/biliary system MP:0005370 9.8 CDKN2A IL2 KIT NRAS VEGFA
15 normal MP:0002873 9.73 BRCA2 CIITA KIT NRAS PDCD6 VEGFA
16 pigmentation MP:0001186 9.46 CDKN2A KIT MC1R NRAS
17 reproductive system MP:0005389 9.43 BRCA2 CDKN2A IL2 KIT VEGFA BAP1
18 respiratory system MP:0005388 9.02 BAP1 CDKN2A IL2 KIT VEGFA

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 1 347396-82-1 459903
2 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
3 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
6
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
9
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
10
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
12
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
13
nivolumab Approved Phase 2, Phase 3 946414-94-4
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
16
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
17
Imidazole Experimental Phase 3,Phase 2 288-32-4 795
18
Fotemustine Experimental Phase 3,Phase 2
19 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
20
QS 21 Phase 3 141256-04-4
21 Vaccines Phase 3,Phase 2,Phase 1
22 Alkylating Agents Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Analgesics Phase 3,Phase 1,Phase 2
25 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2
26 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antiviral Agents Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
29 Micronutrients Phase 3,Phase 2,Phase 1
30 Nicotinic Acids Phase 3,Phase 2,Phase 1
31 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
32 Trace Elements Phase 3,Phase 2,Phase 1
33 Vitamin B Complex Phase 3,Phase 2,Phase 1
34 Vitamins Phase 3,Phase 2,Phase 1
35 Liver Extracts Phase 3,Phase 2
36 Freund's Adjuvant Phase 3,Phase 2,Phase 1
37 Anti-HIV Agents Phase 3,Phase 1,Phase 2
38 Anti-Retroviral Agents Phase 3,Phase 1,Phase 2
39 Interleukin-2 Phase 3,Phase 2,Phase 1
40 Albumin-Bound Paclitaxel Phase 3,Phase 2
41 Antimitotic Agents Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
43 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
45 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
46 Interferon-alpha Phase 3,Phase 2,Phase 1
47 interferons Phase 3,Phase 2,Phase 1
48 Endothelial Growth Factors Phase 3
49 Mitogens Phase 3
50 Folate Nutraceutical Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 191)

id Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
3 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
4 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
5 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed NCT01368276 Phase 3 Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
6 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3 cisplatin;dacarbazine
7 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
8 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
9 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
10 Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3 Dacarbazine;Ipilimumab;Pembrolizumab
11 Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) Recruiting NCT02821013 Phase 3
12 Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma Recruiting NCT01826864 Phase 3
13 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting NCT01274338 Phase 3
14 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
15 Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Suspended NCT02339571 Phase 2, Phase 3
16 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
17 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
18 A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma Terminated NCT01006252 Phase 3 Tasisulam;Paclitaxel
19 High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Terminated NCT00003641 Phase 3
20 High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma Withdrawn NCT00447356 Phase 3 recombinant interferon alfa
21 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
22 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
23 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
24 Pain Relief - Tramadol Versus Ibuprofen Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
25 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
26 Vaccine Therapy in Treating Patients With Malignant Melanoma Unknown status NCT00128583 Phase 2
27 Vaccine Therapy in Treating Patients With Stage IV Melanoma Unknown status NCT00126685 Phase 1, Phase 2
28 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Unknown status NCT00086866 Phase 2
29 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Unknown status NCT00085397 Phase 2
30 Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma Unknown status NCT00538005 Phase 1, Phase 2 oxaliplatin;sorafenib tosylate
31 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
32 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
33 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
34 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
35 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
36 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
37 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
38 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
39 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
40 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
41 Taxoprexin® Treatment for Advanced Eye Melanoma Completed NCT00244816 Phase 2 Taxoprexin
42 Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Completed NCT00471887 Phase 2
43 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
44 High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes Completed NCT00463892 Phase 2
45 Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Completed NCT00071981 Phase 2
46 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
47 Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Completed NCT01435369 Phase 2 CT-011
48 Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma Completed NCT00039325 Phase 1, Phase 2
49 Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Completed NCT00089193 Phase 2
50 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Completed NCT00118274 Phase 1, Phase 2 cyclophosphamide

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

Genetic tests related to Ocular Melanoma:

id Genetic test Affiliating Genes
1 Intraocular Melanoma 29

Anatomical Context for Ocular Melanoma

MalaCards organs/tissues related to Ocular Melanoma:

39
Eye, Liver, Lymph Node, T Cells, Skin, Testes, Kidney

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 334)
id Title Authors Year
1
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
2
Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )
2017
3
Dry Eye Syndrome After Proton Therapy of Ocular Melanomas. ( 28586953 )
2017
4
PRL-3/PTP4A3 phosphatase regulates integrin I^1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )
2017
5
Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )
2017
6
Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )
2017
7
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )
2017
8
Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )
2016
9
Metastatic melanoma after 23a88years of primary ocular melanoma. ( 27881589 )
2016
10
Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )
2016
11
Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )
2016
12
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )
2016
13
Tumor-specific frequencies and ocular melanoma. ( 27552371 )
2016
14
EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )
2016
15
The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )
2016
16
Imaging of ocular melanoma metastasis. ( 27168029 )
2016
17
Metastatic Ocular Melanoma to the Liver Exhibits Infiltrative and Nodular Growth Patterns. ( 27476775 )
2016
18
Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )
2016
19
Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )
2015
20
Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )
2015
21
A challenging case of ocular melanoma. ( 26429178 )
2015
22
Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )
2015
23
Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )
2015
24
Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )
2015
25
Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )
2015
26
Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )
2014
27
Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )
2014
28
Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )
2014
29
Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )
2014
30
SECONDARY NEUTRON DOSES IN PROTON THERAPY TREATMENTS OF OCULAR MELANOMA AND CRANIOPHARYNGIOMA. ( 24222710 )
2013
31
Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. ( 22766897 )
2013
32
Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )
2013
33
Ocular melanoma: an overview of the current status. ( 23826405 )
2013
34
Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. ( 23057648 )
2013
35
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. ( 23799844 )
2013
36
Left ventricular metastasis from ocular melanoma: a new, rare, and unusual pathway? ( 23816109 )
2013
37
Ocular melanoma metastasizing to intra-abdominal lymph nodes. ( 23762736 )
2013
38
Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. ( 24141377 )
2013
39
Diffusion-weighted imaging of ocular melanoma. ( 23614974 )
2013
40
The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )
2013
41
Solitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma. ( 23424696 )
2013
42
Ocular melanoma and mammary mucinous carcinoma in an African lion. ( 23009723 )
2012
43
Survival and complications following I^ knife radiosurgery or enucleation for ocular melanoma: a 20-year experience. ( 22231777 )
2012
44
Ocular melanoma: what's new? ( 22234256 )
2012
45
Ocular melanoma in a patient successfully treated for diffuse malignant peritoneal mesothelioma: a case report. ( 22613358 )
2012
46
Baker's Cyst on F-18 FDG PET/CT in a Patient with Ocular Melanoma. ( 23486655 )
2012
47
Ocular melanoma metastasis to the cervical spine. ( 22245271 )
2012
48
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. ( 22545102 )
2012
49
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. ( 22207316 )
2012
50
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-I_B pathways. ( 22653968 )
2012

Variations for Ocular Melanoma

ClinVar genetic disease variations for Ocular Melanoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
2 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
3 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
4 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for Ocular Melanoma

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.65 CDKN2A CIITA IL2 MC1R VEGFA
2 ovarian follicle development GO:0001541 9.4 KIT VEGFA
3 pigmentation GO:0043473 9.37 KIT MC1R
4 T cell differentiation GO:0030217 9.32 IL2 KIT
5 somatic stem cell division GO:0048103 9.16 CDKN2A KIT
6 positive regulation of protein kinase C signaling GO:0090037 8.96 MC1R VEGFA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.8 IL2 KIT VEGFA

Sources for Ocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....